IV Adult & adolescent Infections 4 g/0.5 g every 8 hr. Nosocomial pneumonia & bacterial infections in neutropenic patients 4 g/0.5 g every 6 hr. Renal impairment w/ severe pneumonia 4 g/0.5 g every 6 hr. Complicated UTI including pyelonephritis, complicated intra-abdominal infections, skin & soft tissue infections including diabetic foot infections 4 g/0.5 g every 8 hr. Patients on haemodialysis 2 g/0.25 g every 4 hrs. CrCl >40 mL/min No dose adjustments; 20-40 mL/min Max: 4 g/0.5 g every 8 hrs; <20 mL/min Max: 4 g/0.5 g every 12 hrs.
Hypersensitivity to penicillins, other β-lactam agents (eg, cephalosporin, monobactam or carbapenem) & other allergens. May cause severe cutaneous adverse reaction eg, SJS & TEN. Life threatening severe, persistent diarrhoea may manifest antibiotic-induced pseudomembranous colitis. Super-infections may result in emergence of resistant organisms. Leukopenia & neutropenia may occur during prolonged therapy. Monitor closely for skin rash (discontinue if lesions progress); serum levels of MTX to avoid toxicity. Perform assessment of hematopoietic function periodically; appropriate coagulation tests more frequently. Monitor serum levels of MTX to avoid toxicity. Abnormalities of coagulation tests, eg, clotting time, platelet aggregation & prothrombin time associated in bleeding manifestations; discontinue antibiotic & initiate therapy.
Concomitant use may lead to prolongation of neuromuscular blockade of vecuronium; increase incidence of acute kidney injury w/ vancomycin; reduce excretion of MTX. May affect blood coagulation system including thrombocyte function. Produces longer t½ & lower renal clearance w/ probenecid.
J01CR05 - piperacillin and beta-lactamase inhibitor ; Belongs to the class of penicillin combinations, including beta-lactamase inhibitors. Used in the systemic treatment of infections.
Sign Out
